Everest Medicines Limited (HKG:1952)
35.34
-0.32 (-0.90%)
Apr 29, 2026, 4:08 PM HKT
Everest Medicines Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Net Income | -297.77 | -1,041 | -844.46 | -247.28 | -1,009 | Upgrade
|
| Depreciation & Amortization | 153.57 | 128.62 | 72.75 | 40.23 | 30.76 | Upgrade
|
| Other Amortization | 2.96 | 5 | 4.03 | 2.55 | 0.37 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.03 | - | 1.43 | -1,320 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 333.23 | 356.34 | 51.97 | 16.49 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 13.47 | 0.01 | -0.85 | 21.75 | - | Upgrade
|
| Loss (Gain) on Equity Investments | 39.15 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 131.78 | 91.1 | 73.42 | 206.5 | 224.98 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.08 | 0.22 | - | - | - | Upgrade
|
| Other Operating Activities | -440.4 | -48.35 | -46.19 | 153.15 | -11.67 | Upgrade
|
| Change in Accounts Receivable | -136.52 | -313.93 | -44.64 | -5.17 | -0.05 | Upgrade
|
| Change in Inventory | -18.19 | 2.86 | -7.31 | -11.19 | -0.45 | Upgrade
|
| Change in Accounts Payable | 291.09 | 106.69 | -116.55 | 70.43 | 73.97 | Upgrade
|
| Change in Other Net Operating Assets | -165.03 | 33.32 | 87.22 | -83.63 | -39.13 | Upgrade
|
| Operating Cash Flow | -92.56 | -679.51 | -769.19 | -1,156 | -729.94 | Upgrade
|
| Capital Expenditures | -64.01 | -65.41 | -117.34 | -355.92 | -109.95 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0.06 | 0.31 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -284.33 | -138.75 | 1,432 | 488.17 | -865.87 | Upgrade
|
| Investment in Securities | -369.75 | 1,179 | -568.77 | -1,161 | - | Upgrade
|
| Other Investing Activities | 35.72 | - | 6.57 | - | - | Upgrade
|
| Investing Cash Flow | -692.71 | 974.4 | 752.5 | -1,028 | -975.82 | Upgrade
|
| Long-Term Debt Issued | 867.31 | 70 | 451.46 | - | - | Upgrade
|
| Total Debt Issued | 867.31 | 70 | 451.46 | - | - | Upgrade
|
| Long-Term Debt Repaid | -520.96 | -43.08 | -463.2 | -30.59 | -23.66 | Upgrade
|
| Net Debt Issued (Repaid) | 346.35 | 26.92 | -11.74 | -30.59 | -23.66 | Upgrade
|
| Issuance of Common Stock | 1,449 | 30.56 | 29.79 | 5.28 | 5.86 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -58.71 | Upgrade
|
| Other Financing Activities | -22.42 | -19.68 | -7.95 | - | - | Upgrade
|
| Financing Cash Flow | 1,773 | 37.8 | 10.1 | -25.31 | -76.51 | Upgrade
|
| Foreign Exchange Rate Adjustments | -27.51 | 28.72 | 38.87 | 59.83 | -58.81 | Upgrade
|
| Net Cash Flow | 959.92 | 361.41 | 32.28 | -2,149 | -1,841 | Upgrade
|
| Free Cash Flow | -156.57 | -744.92 | -886.53 | -1,512 | -839.89 | Upgrade
|
| Free Cash Flow Margin | -9.17% | -105.41% | -703.97% | -11817.36% | -1555344.44% | Upgrade
|
| Free Cash Flow Per Share | -0.47 | -2.32 | -2.83 | -5.08 | -2.86 | Upgrade
|
| Cash Interest Paid | 20.33 | 19.68 | 7.95 | - | - | Upgrade
|
| Levered Free Cash Flow | -228.39 | -689.33 | 2,356 | -2,031 | -1,339 | Upgrade
|
| Unlevered Free Cash Flow | -213.84 | -675.46 | 2,371 | -2,028 | -1,336 | Upgrade
|
| Change in Working Capital | -28.65 | -171.07 | -81.28 | -29.56 | 34.35 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.